OCSEarnings•globenewswire•
Oculis Reports Q2 2025 Financial Results and Provides Company Update
Sentiment:Negative (20)
Summary
ZUG, Switzerland, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced results for the second quarter ended June 30, 2025 and provided an overview of the Company’s progress.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 21, 2025 by globenewswire